Octave Presents Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights

MENLO PARK, Calif.--(BUSINESS WIRE)-- Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), announced data focused on the company’s novel MS Disease Activity (MSDA) test. The data was shared in a poster presentation at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting.

The poster, titled Multivariate Proteomic MS Disease Activity Test Results Surfaces Both Individual Patient and Clinical Practice Population Insights (Qureshi, F., et al.), highlighted the MSDA test’s observed score distributions in a well-controlled population of patients with MS, and showed that in a population of 222 patients, results from the test could track an individual patient’s level of disease activity (DA) as well as effectively monitor DA across the entire clinic’s population.

The Octave MSDA test is a novel, clinically-validated biomarker blood test that measures patients’ disease biology, revealing underlying activated pathways and mechanisms, including quantitative analysis of serum proteins, to create unique MS signatures. The test is one dimension of the Octave MS Precision Care Solution, in development to address the complex unmet needs of MS and other neurodegenerative diseases.

“The MS community is striving to help facilitate objective, value-based care for a patient population that, to this point, has been difficult to manage and track – it is critical that we better characterize these patients’ underlying biology and disease activity over time in clinical practice to optimize their treatment,” said Mike Edgeworth, MD, Chief Population Health Officer of Octave. “We see the continued validation of Octave’s MSDA test as encouraging steps as we build the model for the future of MS management and beyond, producing insights that will benefit not only individual patients, but whole practices and entire health systems as well.”

Previous data from the company demonstrated that the MSDA test is strongly associated with radiographic and clinical disease activity endpoints. Multiple studies, including clinical validation results and independent cohort replication, have shown that the test can serve as a quantitative and objective tool to enhance the care of MS with the potential to positively impact these patients at a population level.

Data presented by Octave to date support the launch of the company’s precision care solution as the company actively develops novel measurement tools that feed structured analytical data models to improve patient management decisions, create better outcomes, and lower costs, ultimately benefiting patients, their physicians, and the entire health care system.

About Multiple Sclerosis

MS is a chronic, lifelong, debilitating disease that affects approximately three million patients globally (one million of whom are in the US), affecting people as early as in their 20’s with a 3:1 prevalence in women. The disease is driven by autoimmune and inflammatory processes as well as neurodegeneration, including demyelination and axonal damage. Estimated lifetime cost of MS is more than $4.8 million per patient and the estimated annual direct medical cost in the US alone is $63 billion, with a total economic burden of $85 billion.^1,2 MS is ranked second, behind only congestive heart failure, in direct all-cause medical costs. While there are now more than 22 approved treatments called disease modifying treatments, drug prices have continued to rise, costing between $60,000 and $100,000 per year.²

About Octave’s Comprehensive Precision Care Solution

Octave’s fully-integrated precision care solution provides a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS. It provides multiple dimensions of insight to reveal a 360-degree view with a longitudinal perspective of a patient. The first dimension measures the patient’s underlying biology with blood-based biomarkers that quantitatively and objectively assess inflammation, immune modulation, axonal damage, and demyelination. The second dimension includes advanced measurement using improved MRI readings and interpretation to reveal more insights at the CNS layer, including the brain and spine. The final dimension features real-time tracking of symptoms via mobile tools, sensors and wearables to identify changes in disease, and alert care teams. All of this data is integrated into protocols, supported by decision support tools and feeds into a dashboard for ease of use. The Octave Precision Care Solution allows individual and population level views to facilitate better stratification and contextual interventions.

About Octave

Octave was founded to deliver a fully-integrated precision care solution for multiple sclerosis as well as a full range of neurodegenerative diseases. Its comprehensive insights provide neurologists and their patients with objective metrics to facilitate informed care and shared decision making for better patient outcomes. Octave is headquartered in Menlo Park, California.

1. Optum.com. “Six Cost Drivers of Multiple Sclerosis.”
2. Wexler M. #ECTRIMS2021 – Economic Burden of MS in US Exceeded $85B in 2019. Multiple Sclerosis News Today. October 18, 2021. https://multiplesclerosisnewstoday.com/. Accessed June 1, 2022.
3. J.Med Econ.2013; 16(5):639-47

View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005436/en/